Fresenius SE & Co. KGaA Stock
€43.74
Your prediction
Fresenius SE & Co. KGaA Stock
Fresenius is a German healthcare company listed on the Frankfurt and New York stock exchanges under the symbol FSNUF. The company is primarily engaged in the production and distribution of medical devices, pharmaceuticals, and services related to renal dialysis, critical care, and hospital operations. With over 290,000 employees and operations in more than 100 countries, Fresenius is one of the largest healthcare providers in the world. The company has experienced steady growth over the years, driven by its innovative product portfolio, strategic acquisitions, and a focus on operational efficiency.
Pros and Cons of Fresenius SE & Co. KGaA in the next few years
Pros
Cons
Performance of Fresenius SE & Co. KGaA vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Fresenius SE & Co. KGaA | -0.550% | -0.794% | 4.143% | 46.729% | 30.645% | 44.691% | 3.136% |
| Fresenius SE & Co. KGaA ADR | -2.700% | -0.917% | 0.935% | 46.939% | 31.707% | 45.946% | 0.935% |
| Fresenius Medical Care AG & Co KGaA ST | -1.270% | -1.074% | -0.420% | 28.512% | 12.937% | -2.964% | -33.262% |
| Quest Diagnostics Inc. | -0.580% | 1.536% | -2.049% | 20.473% | 7.212% | 26.548% | 57.716% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Analyzing the financials of Fresenius (FSNUF) offers insights into a multifaceted healthcare provider navigating a complex landscape. The company exhibits a blend of strengths and challenges that reveal important considerations for investors and stakeholders alike. The financial statements reflect a robust operational presence, although there are areas requiring caution. Overall, a nuanced perspective is essential when evaluating Fresenius' financial stability and growth potential.
Pros of Fresenius Financials:
Strong Revenue Generation: With total revenue reported at approximately €22.46 billion for the trailing twelve months, Fresenius demonstrates robust capacity to generate income. This solid revenue stream, coupled with a consistent gross profit of around €10.73 billion, showcases the company’s ability to maintain a profitable operation within the healthcare sector.
Comments
News
EQS-Adhoc: Fresenius SE & Co. KGaA: Fresenius announces its intention to reduce its stake in Fresenius Medical Care AG from currently around 32.2% to no less than 25% plus one share
Fresenius SE Stock: Shares Rally Near 52-Week High
Fresenius SE demonstrated remarkable momentum on the Frankfurt Stock Exchange today, with shares climbing 1.1 percent to reach €37.07. The stock, which opened at €36.50, achieved an intraday peak of
Fresenius SE Stock: Accelerates Exit from Vamed Projects
Fresenius SE, the German healthcare giant, is expediting its strategic realignment through a swift divestment of Vamed's international project operations. The DAX-listed company has announced the